Prescription drug prices dropped 3.1% over the last twelve months. That's the largest decline in over sixty years — since 1963, back when JFK was in the White House and a bottle of aspirin cost a nickel.
Every pharmaceutical lobbyist in Washington swore this was impossible.
Overall medicinal drug prices fell 2.7% over the twelve months ending in July, while the six-month annualized rate plunged at an even steeper 6.6%. These aren't projections or campaign promises. These are hard federal data points.
The engine behind the collapse has a name: TrumpRx. President Trump launched the direct-to-consumer prescription drug website, TrumpRX.gov, back in February 2026, and its impact has been a wrecking ball to Big Pharma's pricing model. GLP-1 weight-loss drugs that insurance companies had been charging over $1,000 per month suddenly became available at a starting dose cost of $150. The same drugs — Wegovy from Novo Nordisk, Zepbound from Eli Lilly — that had been priced as luxury goods were suddenly within reach of ordinary Americans.
Then came the Medicare pilot program in July 2026, offering weight-loss drugs at $245 per month. That's a quarter of what patients were paying before Trump's team got involved.
White House spokesman Kush Desai didn't mince words: "No president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump. This is a direct result of the President's willingness to push the envelope with bold policies that actually put Americans and America First."
A senior White House official added context on the speed of the rollout: "In a matter of months, we got up and running these discounts in a way that they were meaningful for American patients."
The broader strategy includes Most Favored Nation drug pricing — the policy that says Americans shouldn't pay more for the same pill than patients in Canada or Germany. The pharmaceutical industry spent years lobbying against it. They called it unworkable. They said it would destroy innovation. They warned of shortages, rationing, the end of medical progress as we know it.
The usual objection goes something like this: prices would have come down anyway due to market forces. Which is an interesting theory to float after six decades of prices going in exactly one direction — up. Sixty years of "market forces" produced nothing but higher costs. Six months of TrumpRx produced the sharpest reversal since the Kennedy administration.
This isn't a one-drug story or a narrow rebate trick. The BLS data covers prescription drugs across the board. The decline is broad, measurable, and accelerating. The six-month annualized rate of 6.6% suggests the trend is getting stronger, not fading.